ABT-199, a new Bcl-2–specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia
Top Cited Papers
- 21 March 2013
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 121 (12), 2285-2288
- https://doi.org/10.1182/blood-2013-01-475855
Abstract
Key Points ABT-199, a new Bcl-2–specific BH3 mimetic, is efficacious in vivo against mouse lymphomas without provoking thrombocytopenia. Treating mouse lymphomas with BH3 mimetic ABT-737 combined with bortezomib or purvalanol achieved long-term remission.This publication has 23 references indexed in Scilit:
- Noxa Up-regulation and Mcl-1 Cleavage Are Associated to Apoptosis Induction by Bortezomib in Multiple MyelomaCancer Research, 2007
- Programmed Anuclear Cell Death Delimits Platelet Life SpanCell, 2007
- Bcl-2 family proteins are essential for platelet survivalCell Death & Differentiation, 2007
- Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737JCI Insight, 2007
- Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemiaCancer Cell, 2006
- The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralizedCancer Cell, 2006
- Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myelomaBlood, 2005
- An inhibitor of Bcl-2 family proteins induces regression of solid tumoursNature, 2005
- Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease.Proceedings of the National Academy of Sciences of the United States of America, 1991
- Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2Nature, 1990